Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 614 participants.

Also called NCT03409107

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 614 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03409107
  • EudraCT 2017-002270-39
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Brazil, Canada, France, Italy, Mexico, Poland, Romania, Russia, South Korea, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03409107. Randomized; double masking; primary purpose treatment. Start 2018-03-05 (actual); primary completion 2020-10-07 (actual). Results posted on 2021-11-03.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)
Condition
Anaemia
Intervention (Drug)
Daprodustat (GSK1278863)
Intervention (Drug)
Placebo
Intervention (Drug)
Iron therapy
Lead sponsor
GlaxoSmithKline (class: industry)

Record details

Record id
cardio:ct-nct03409107
Content hash
6a168dc4ece9140f4d5100c5d7169a149ad65f1d8c19df6e06921008b23dd9dc